Compare Novartis AG (NVS) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Simon Property Group Inc — how do they compare? Novartis AG trades at $143.11 (market cap $268.57B), while Simon Property Group Inc trades at $199.79 (market cap $64.59B). The key difference: Novartis AG is far larger — about 4.2× Simon Property Group Inc's market cap, and Simon Property Group Inc pays the higher dividend (4.46%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Simon Property Group Inc for 99 Days on average.
| NVS | SPG | |
|---|---|---|
Market Cap | $268.57B | $64.59B |
Volume | 1,532,573 | 1,093,907 |
Sector | Health | Real Estate |
52-Week High | $168.62 | $236.70 |
52-Week Low | $121.80 | $173.35 |
Typical Hold Time | 82 Days | 99 Days |
Enterprise Value | $309.89B | $93.03B |
Dividend Yield | 3.31% | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Simon Property Group (SPG) trades at $197.59, down 2.06% amid bearish technical signals, though fundamentals remain strong with robust profitability margins (net income margin 66.57%) and consistent revenue growth. Recent Q2 2026 earnings missed expectations, but Q4 2025 and Q1 2026 beat estimates. The company maintains solid cash flow from operations ($4.14B in 2025) and a raised dividend, while facing headwinds from rising bond yields and debt maturities.
Outlook: SPG offers value with a P/E of 14.09 below sector averages and a 42% analyst buy rating, targeting 13% upside to consensus. Risks include interest rate sensitivity, high leverage ($24.21B debt), and retail sector volatility. The stock's current pullback may present a buying opportunity for income investors, supported by strong leasing demand and strategic initiatives like the Simon Media Network launch.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
